October 24th, 2026AAO 2026: GLP-1RA initiation not linked to anti-VEGF burden in DMEIRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.Read more
October 22nd, 2026Murtaza K. Adam, MD, on pearls for the Yamane scleral-fixated IOL techniqueMurtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.Read more
October 20th, 2026NeuroOp Guru at AAO 2026: Blurry vision in MS isn’t always a relapseAndrew G. Lee, MD, and Drew Carey, MD, break down the link between optic neuritis and uveitis in central nervous system demyelinating disease.Read more
October 19th, 2026AAO 2026: Rethinking dry eye as a spectrum of ocular painAnat Galor, MD, MSPH, discusses subtyping dry eye, emerging diagnostic tools, and when to consider oral neuromodulation.Read more
October 19th, 2026Beyond slowing atrophy: Optogenetic therapy targets vision lost to GAJordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.Read more
October 18th, 2026AAO 2026: Preventing complications in uveitic cataract surgeryAt AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.Read more
November 1st, 2026FAQ: Diabetic eye disease awareness month 2026An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.Read more
October 31st, 2026Q&A: Phentolamine for presbyopia: a non-miotic route to near visionThe FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia. Read more